JPMorgan analyst Brian Essex raised the firm’s price target on Cellebrite (CLBT) to $28 from $24 and keeps an Overweight rating on the shares as part of a Q4 earnings preview for the security software group. The firm thinks growth will continue to accelerate for Cellebrite and expects its ongoing platform expansion, deeper government penetration, and migration to its subscription platform will result in better long-term fundamental strength.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- CLBT Upcoming Earnings Report: What to Expect?
- Cellebrite announces availability of GenAI capabilities within Guardian
- Cellebrite price target raised to $28 from $21 at Needham
- Cellebrite price target raised to $24 from $22 at Deutsche Bank
- Cellebrite Strengthens Board with New Appointments for 2025 Growth